FreeStyle Libre 3 system
The world's smallest sensor streams readings directly to your smartphone*, so you can know your glucose levels with just a quick glance†.
Try it for free‡
Performance you can count on2
So you can get back to the things that matter most.
No fingersticks
Painless to apply1 and wear1, without the need for fingersticks§
Accurate
The most accurate2 14-day CGM system helps improve overall glucose controlǁ3,4, lower A1cǁ5 and reduce time in hypoglycemiaǁ3
Discreet
The world’s smallest, thinnest¶ and most discreet1 sensor
Reliable
Optional, real-time glucose alarms# let you know the minute your glucose is too high or too low
Affordable
The most affordable CGM system, even without insurance coverage**1
CGM = continuous glucose monitoring
Stay connected with the apps
With the FreeStyle Libre 3* and LibreLinkUp†† apps, you can monitor your glucose, view reports, and sharedata with loved ones‡‡§§.
Download the app today!
Before you can use your smartphone* for sensor readings, you’ll need to download the FreeStyle Libre 3 app*. Check to see if your smartphone* is compatible here.
Start your journey with the MyFreeStyle program
The MyFreeStyle program will provide guidance on how to use your CGM system to stay on top of your diabetes management.
- Learn how to get the most out of your CGM system
- Track your glucose levels and unlock insights about what impacts them2
- Get guided support that can help you manage your glucose levels
If you are commercially insured or cash paying, you may qualify for a free‡ sensor.
Ready to get started with a FREE‡ trial?
LET'S GO
The FreeStyle Libre 3 system is indicated for use in people with diabetes age 4 and older.
Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.
Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
* The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app.
† 60-minute warm-up required when starting the sensor.
‡ or ♢ Eligible patients will receive one (1) FreeStyle Libre 3 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1, Type 2, or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 3 sensor. Patients ages 4-17 are eligible to receive an offer for the (1) FreeStyle Libre 3 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 3 sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 3 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursem*nt and is not provided as any inducement for future purchases. The free sample card is not health insurance.
§ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours.
ǁ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.
¶ Among patient-applied sensors.
# Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.
** Based on prescription claims for commercially insured patients starting on the FreeStyle Libre personal CGM systems compared to competitor CGMs. Does not include Medicare, Medicaid, uninsured, and other federal or state healthcare program patients. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
†† The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician.
‡‡ The FreeStyle Libre 3 app is designed to facilitate data sharing between patients and their healthcare providers and caregivers.
§§ The user’s device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
ǁǁ Based on prescription claims for commercially insured patients using the FreeStyle Libre personal CGM systems. Does not include Medicare, Medicaid, uninsured, and other federal or state healthcare program patients. The actual amount a patient pays may vary. The FreeStyle Libre 3 system requires a prescription.
References: 1. Data on File. Abbott Diabetes Care. 2. FreeStyle Libre 3 User's Manual. 3. Bolinder, Jan, et al. "Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial." The Lancet 10057, no. 388 (2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 4. Yaron, Marianna, et al. "Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes." Diabetes Care 42, no. 7 (2019): 1178-1184. https://doi.org/10.2337/dc18-0166. 5. Evans, Mark, et al. "Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta analysis of 75 real-world observational studies." Diabetes Therapy (2022). https://doi.org/10.1007/s13300-022-01253-9.
ADC-56218 v5.0
